The rising interest in potent weight management has resulted in considerable exploration into novel treatments. Lately , Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist , has demonstrated encouraging results in clinical trials, indicating potential for significant w